

International Journal of Experimental and Clinical Pharmacology
Pharmacology

Review

233 Understanding the Activity of Antibiotics in Cerebrospinal Fluid in vitro

Matzneller, P.; Burian, A.; Zeitlinger, M.; Sauermann, R. (Vienna)

Original Papers

207 Effect of Angiotensin-(1-7) on Aortic Response, TNF- α , IL-1 β and Receptor for Advanced Glycation Endproduct in Rat's Adjuvant-Induced Arthritis

Açikalin, Ö.; Bölükbaşı Hatip, F.F.; Tan, R.F.; Hatip-al-Khatib, I. (Denizli)

218 Effect of Evodiamine on CYP Enzymes in Rats by a Cocktail Method

Zhang, Y.; Zhang, D.; Ge, N.; Zhu, G. (Wenzhou); Hao, C.; Zhang, Y. (Luoyang); Chen, R. (Wenzhou)

224 Protective Effect of Naringenin against Lipopolysaccharide-Induced Acute Lung Injury in Rats

Fouad, A.A. (Al-Ahsa/El-Minia); Albuali, W.H.; Jresat, I. (Al-Ahsa)

245 Pifithrin- μ Attenuates Acute Sickness Response to Lipopolysaccharide in C57BL/6J Mice

Zhang, R.; Wang, J.; Hu, Y.; Lu, X.; Jiang, B.; Zhang, W.; Huang, C. (Nantong)

251 Oral Administration of Pregabalin in Rats before or after Nerve Injury Partially Prevents Spontaneous Neuropathic Pain and Long Outlasts the Treatment Period

Wang, R.-R.; Lou, G.-D.; Yu, J.; Hu, T.-T.; Hou, W.-W.; Chen, Z.; Zhang, S.-H. (Hangzhou); Seltzer, Z. (Toronto, Ont.)

259 Isobolographic Analysis of Interaction for Three-Drug Combination of Carbamazepine, Phenobarbital and Topiramate in the Mouse Maximal Electroshock-Induced Seizure Model

Luszczki, J.J. (Lublin)

265 Pitavastatin Exhibits Protective Effects on Podocytes Accompanied by BMP-7 Up-Regulation and Rho Suppression

Ohigashi, M.; Imai, N.; Toba, H.; Kobara, M.; Nakata, T. (Kyoto)

282 Protection on Skin Aging Mediated by Antiapoptosis Effects of the Water Lily (*Nymphaea Tetragona Georgi*) via Reactive Oxygen Species Scavenging in Human Epidermal Keratinocytes

Park, G.; Sim, Y.; Lee, W.; Sung, S.H.; Oh, M.S. (Seoul)

(Continued on inside front cover)

(Continued from front cover)

294 Pre-Treatment Serum C-Reactive Protein Level Is An Independent Risk Factor for Development of Nephrotoxicity in Patients Receiving High-Dose Vancomycin

He, J.; Mao, E.-Q.; Jing, F.; Jiang, H.-T.; Yang, W.-H.; Chen, E.-Z. (Shanghai)

301 Inactivation of Airborne Bacteria and Viruses Using Extremely Low Concentrations of Chlorine Dioxide Gas

Ogata, N.; Sakasegawa, M.; Miura, T.; Shibata, T.; Takigawa, Y.; Taura, K.; Taguchi, K.; Matsubara, K.; Nakahara, K.; Kato, D.; Sogawa, K. (Kyoto); Oka, H. (Osaka)

Short Communication

277 Interaction of $\alpha\beta$ -Methylene ATP with the Cholinergic Twitch Response in the Guinea-Pig Ileum

Donnerer, J.; Liebmann, I. (Graz)

after **306 Contents Vol. 97, 2016**

Pharmacology

International Journal of Experimental and Clinical Pharmacology

Founded 1959 as 'Medicina Experimentalis', continued 1965–1967 as
'Medicina et Pharmacologia Experimentalis'

Founder: R. Domenjoz (1959–1977)

Successors: B.B. Brodie (1968–1977); K. Lederis (1973–1985); K.-F. Sewing (1978–1998);

E.S. Vesell (1970–2000); R. Kato (1992–1995); T. Watanabe (1995–2001);

T. Iijima (2002–2006); M.L. Billingsley (2001–2013)

Editors

J. Donnerer, Graz
K. Takeuchi, Kyoto
K.E. Vrana, Hershey, Pa.

Editorial Board

C. Antoniou, Athens
J. Ahrens, Hannover
L.Z. Benet, San Francisco, Calif.
M.L. Billingsley, Hershey, Pa.
A. Breckenridge, London
K.K. Burkhardt, Silver Spring, Md.
G. Coruzzi, Parma
S. Dhein, Leipzig
T.L. Goodfriend, Madison, Wisc.
L.S. Harris, Richmond, Va.
M. Hirafuji, Ishikari-Tobetsu
M.D. Hollenberg, Calgary, Alta.
M. Inui, Yamaguchi
K. Ishii, Yamagata
C. Joukhadar, Boston, Mass.

Y. Kamisaki, Osaka
N. Kaplowitz, Los Angeles, Calif.
A. Kawabata, Osaka
A. Levitzki, Jerusalem
B.R. Lucchesi, Ann Arbor, Mich.
W.E. Müller, Frankfurt am Main
N.H. Neff, Columbus, Ohio
J.P. O'Callaghan,
Morgantown, W.Va.
K. Pennypacker, Tampa, Fla.
S. Saha, Kansas City, Mo.
C. Scarpignato, Nantes
C.D. Smith, Charlestown, S.C.
E. Taira, Iwate
C. Zeng, Chongqing City

Submission

The journal publishes articles dealing with all aspects of experimental and clinical pharmacology. Papers dealing with mechanistic aspects at a molecular level are particularly encouraged. They can be full articles as well as short communications of investigative findings. Reviews, comments and perspective notes on timely topics are specifically welcome. Reviews in which a specific field is reviewed through an exhaustive literature survey. An Abstract is required and should be divided into Background, Summary and Key Messages. Review Articles should consist of a maximum of 4,000 words. We consider investigations dealing with biological extracts or with phytopharmaceutical preparations as outside the scope of our journal. Only papers written in English are considered and should be submitted using the online submission website at:

www.karger.com/pha

or sent as e-mail attachment (the preferred word-processing package is MS-Word) to the Editorial Office:

pha@karger.com

Prof. J. Donnerer
S. Karger AG
Editorial Office 'Pharmacology'
P.O. Box
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1356
Fax +41 61 306 1434

Names, postal and e-mail addresses of 4 experts in the appropriate area of research should accompany each manuscript. Referees suggested should not be from the same institution or be research collaborators of the author(s).

Conditions

All manuscripts are subject to editorial review. Manuscripts which do not properly consider ethical issues for humans or animals will not be accepted for publication. In the 'Methods' section, it is recommended to mention the approval given by the responsible authorities. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of *Pharmacology* and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflicts of Interest

Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the article.

Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Ethics

Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute's committee on human research. Further, they should also state that animal experiments conform to institutional standards.

Arrangement

Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract of Reviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review.

Abstract of Original Papers or Short Communications: Each paper needs an abstract of up to 10 lines.

Drug names: Authors are requested to use International non-proprietary names definitely recommended or, if no final recommendation has been made, proposed by the World Health Organisation (WHO). The use of laboratory code numbers necessitates prior explanation by chemical name or structural formula.

Footnotes: Avoid footnotes.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for

reproduction (max. size 180 × 223 mm) or provide crop marks. Each illustration must be labeled with its number and the first author's name. The final resolution for b/w half-tone and color illustrations must be 300 dpi after scaling. Line drawings require 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (for detailed instructions, see <http://www.karger.com/pha>).

Color illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples

(a) *Papers published in periodicals:* Sun J, Koto H, Chung KF: Interaction of ozone and allergen challenges on bronchial responsiveness and inflammation in sensitised guinea pigs. *Int Arch Allergy Immunol* 1997;112:191–195.

(b) *Papers published only with DOI numbers:* Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. *Int Arch Allergy Immunol* DOI: 10.1159/000063858.

(c) *Monographs:* Matthews DE, Farewell VT: *Using and Understanding Medical Statistics*, ed 3, revised. Basel, Karger, 1996.

(d) *Edited books:* Parren PWHI, Burton DR: *Antibodies against HIV-1 from phage display libraries: Mapping of an immune response and progress towards antiviral immunotherapy*; in Capra JD (ed): *Antibody Engineering*. Chem Immunol. Basel, Karger, 1997, vol 65, pp 18–56.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material

Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Self-Archiving/Green Open Access

Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution's internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

- Be used for noncommercial purposes only
- Be linked to the final version on www.karger.com
- Include the following statement:

'This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at [http://www.karger.com/?doi=\[insert DOI number\]](http://www.karger.com/?doi=[insert DOI number]).'

It is the author's responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author's behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author's Choice™ (Gold Open Access) articles, see Author's Choice™.

Author's Choice™

Karger's Author's Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice. The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

- Follow the terms of the relevant Creative Commons license
- Be linked to the final version on www.karger.com
- Include the following statement:

'The final, published version of this article is available at [http://www.karger.com/?doi=\[insert DOI number\]](http://www.karger.com/?doi=[insert DOI number]).'

It is the author's responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)

The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author's Choice™, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders' requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Page Charges

There are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is equal to approx. 14 manuscript pages (including tables, illustrations and references).

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer's errors are charged to the author.

Reprints

Order form and price list is sent with the pdf proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

ISSN Print Edition: 0031-7012
ISSN Online Edition: 1423-0313

Journal Homepage: www.karger.com/pha

Publication Data: *Pharmacology* is published 12 times a year. Volumes 97-98, each with 6 issues, appear in 2016.

Copyright: © 2016 S. Karger AG, Basel (Switzerland). All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.

Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Subscription Rates: Subscriptions run for a full calendar year. Prices are given per year.

Personal subscription:

Print or Online	Print+Online combined
CHF 1768.00	CHF 1868.00
EUR 1578.00	EUR 1658.00
USD 1901.00	USD 2009.00

postage and handling (added to print and print+online)
 CHF 91.20 Europe, CHF 134.40 Overseas

EUR 81.60
 USD 124.80

Institutional subscription:

Print or Online	Print+Online combined
CHF 3535.00	CHF 4065.00
EUR 3156.00	EUR 3629.00
USD 3801.00	USD 4371.00

postage and handling (added to print and print+online)
 CHF 114.00 Europe, CHF 168.00 Overseas

EUR 102.00
 USD 156.00

Back Volumes and Single Issues: Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.ch.

Bibliographic Indices: This journal is regularly listed in bibliographic services, including *Current Contents*® and PubMed/MEDLINE.

Photocopying: This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to

Copyright Clearance Center Inc.
 222 Rosewood Drive
 Danvers, MA 01923 (USA)

A copy of the first page of the article must accompany payment. Consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. In these cases, specific written permission must be obtained from the copyright owner, S. Karger AG, P.O. Box CH-4009 Basel (Switzerland).

Subscription Orders:

Orders can be placed at agencies, bookstores, directly with the Publisher

S. Karger AG

Medical and Scientific Publishers
 Allschwilerstrasse 10
 CH-4009 Basel
 Switzerland

t: +41 61 306 11 11
 f: +41 61 306 12 34
 e: karger@karger.com
 w: www.karger.com

(for courier services only:
 Allschwilerstrasse 10
 CH-4055 Basel)

or further Karger offices
 or representatives:

Germany
S. Karger GmbH
 Postfach
 79095 Freiburg
 Deutschland
 (Hausadresse: Wilhelmstrasse 20A,
 79098 Freiburg)
 t: +49 761 45 20 70
 f: +49 761 45 20 714
 e: information@karger.de
 w: www.karger.de

Japan
Karger Japan, Inc.
 Shiba Daimon Asahi Bldg. 2F
 1-2-23 Shiba Daimon
 Minato-ku
 Tokyo 105-0012
 Japan
 t: +81 3 6435 6242
 f: +81 3 6435 6244
 e: publisher@karger.jp
 w: www.karger.jp

USA
S. Karger Publishers, Inc.
 26 West Avon Road
 P.O. Box 529
 Unionville, CT 06085
 USA
 Toll free: +1 800 828 5479
 t: +1 860 675 7834
 f: +1 860 675 7302
 e: kargerusa@karger.com

France
Enter & Read
 Albertine Luginbuhl
 23, rue du Départ, boîte 37
 75014 Paris
 France
 t: +33 (0) 6 81 04 76 85
 e: albertineluginbuhl@orange.fr

South East Asia, China and Taiwan
Karger Regional Office (Malaysia)
 Level 28-03-03A, PJ Exchange
 No. 16A, Persiaran Barat
 46050 Petaling Jaya
 Selangor Darul Ehsan
 Malaysia
 t: +60 3 7962 0158
 f: +60 3 7962 0001
 e: service@karger.cn; r.chew@karger.cn

Karger China

51F Raffles City Centre
 268 Xi Zang Middle Road
 Huang Pu District
 Shanghai 200001
 P.R. China
 t: +86 21 2312 7673
 f: +86 21 2312 7777
 e: service@karger.cn
r.chew@karger.cn
 w: www.karger.com

India, Bangladesh, Sri Lanka
Karger India
 Plot No. 17, Yusuf Sarai Market
 B.L. Glass Building, 2nd Floor
 Sri Aurobindo Marg
 New Delhi 110 016
 India
 t: +91 11 46029 633
 f: +91 11 46029 634
 c: +91 98 91052 128
 e: r.kumar@kargerindia.com
 w: www.karger.com

Change of Address:

Both old and new address should be sent to the subscription source.

Pharmacology

Karger Gazette




(Continued)

The Aging Issue

G. Wick

age because our cultural tradition by far...
Gerontology: death with an issue that...
The aging process is a complex...
The aging process is a complex...
The aging process is a complex...

From the above mentioned...
The aging process is a complex...
The aging process is a complex...
The aging process is a complex...



When we were first...
Anatomy & Art through the Ages...
The history of anatomy...
The history of anatomy...
The history of anatomy...



Dear Reader...
125 Years Karger Publishers...
The history of Karger...
The history of Karger...
The history of Karger...

Stimulating reading in and around the world of medicine

The biomedical themes of the *Karger Gazette* are topical, urgent, exciting. Its articles, written by experts from all over the world, provide a wide audience with the basic issues, new findings and controversies in a lively and readable style. Alongside invited contributions, each issue carries attractively presented support material, such as informative graphics, historical summaries, interviews, or portraits of individuals and institutions. The *Karger Gazette* is published in newspaper format and appears once a year.

And what's more – it's free!
To see behind the cover, please register for your free print subscription or read it online.


www.karger.com/gazette

- Current issue:
- ### 125 Years Karger Publishers
- Read about the STM publishing business in the digital age
 - Have a look at the portraits of Karger's journal and book series editors
 - Meet three world-renowned scientists who talk about their careers and how they define progress



S. Karger AG
Karger Gazette
Allschwilerstrasse 10
CH-4009 Basel (Switzerland)
E-Mail gazette@karger.com
www.karger.com/gazette

The first comprehensive overview on the topic



Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

Editors
Gerhard Rogler
Hans Herfarth
Toshifumi Hibi
Ole Haagen Nielsen

Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

Editors: Rogler, G. (Zurich); Herfarth, H. (Chapel, Hill, N.C.); Hibi, T. (Tokyo); Nielsen, O.H. (Copenhagen)

VIII + 240 p., 26 fig., 17 in color, 15 tab., 2015

CHF 198.00 / EUR 185.00 / USD 233.00

(hard cover)

CHF 238.00 / EUR 222.00 / USD 280.00 (online)

Online version for institutional purchase

Prices subject to change, VAT not included

EUR price for eurozone countries, USD price for

USA and Latin America only

ISBN 978-3-318-05473-6 (hard cover)

e-ISBN 978-3-318-05474-3

Frontiers of Gastrointestinal Research, Vol. 34
Series Editor: Sakamoto, C. (Tokyo)



Dear Librarian

I have reviewed this publication and would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

The introduction of anti-tumor necrosis factor (TNF) antibodies into the treatment of patients with IBD about fifteen years ago has dramatically improved the quality of life for patients with severe Crohn's disease and ulcerative colitis. But despite the fact that this therapeutic approach has been around for quite some time, there has been no comprehensive overview to date.

The book at hand aims to amend this shortcoming, presenting for the first time a thorough overview on TNF action, mechanisms of anti-TNF therapy, treatment strategies, side effects, monitoring, biosimilars and related issues.

Including state-of-the-art information and research results, this publication will be a valuable source of information and guide clinicians to the optimal treatment decision, improving the quality of life of patients with IBD. Moreover, rheumatologists or even dermatologists might also find this book of interest.

Contents

• Preface: **Rogler, G. et al.**

Physiological Role of TNF in Mucosal Immunology

- The Effect of TNF- α on the Regulation of Epithelial Function in IBD: **Tsuchiya, K.**
- Physiological Role of TNF in Mucosal Immunology: Regulation of Macrophage/Dendritic Cell Function: **Rivollier, A. et al.**
- Physiological Role of TNF in Mucosal Immunology: Regulation of T-Cell Function: **Scharl, M.**

Pathophysiological Role of TNF in IBD

- Pathophysiological Role of TNF in IBD: TNF and Its Impact on Barrier Function: **Schumann, M.; Kühnel, A.**
- Pathophysiological Role of TNF in IBD: TNF and Its Effect on Innate Immune Defense: **Scharl, M.**
- TNF and Its Impact on Adaptive Immune Mechanisms and Chronic Inflammation: **Siegmund, B.**

Mechanism of Action of Anti-TNF Antibodies

- Binding of Membrane-Bound TNF: **Atreya, R. et al.**
- Apoptosis of T Cells and Monocytes: **Kucharzik, T.**
- Neutralisation of Soluble TNF: **Dreesen, E.; Gils, A.**

General Treatment Considerations

- Recommended Screening Procedures before Treatment with Anti-TNF Agents: **Maaser, C.**
- The Risk of Formation of Neutralizing Antibodies: **Clark, J.; Sakuraba, A.**
- TNF Antagonist Trough Concentrations and Treatment Efficacy in IBD: **Vande Casteele, N.**

Biosimilars

- What Is a Biosimilar? **Neri, D.**
- Is Extrapolation of Safety and Efficacy Data Possible? **Ainsworth, M.**
- Potential Concerns and Questions: **Rogler, G.**

Side Effects of Anti-TNF Therapy

- Psoriasis-Like Lesions and Skin Reactions: **Herfarth, H.H. et al.**
- The Elicitation of Rheumatic Symptoms at Vascular Sites: **Geyer, M.; Müller-Ladner, U.**
- Serum Reaction, Lupus-Like Syndrome: **Schnitzler, F.**

Risks of Anti-TNF Therapy

- Risk of Non-Hematologic Malignancy with Anti-TNF Therapy in IBD: **Jain, A. et al.**
- Risk of Lymphoma: **Nagahori, M.; Watanabe, M.**
- Risk of Serious Infection: **Naganuma, M.**
- Risk of Post-Operative Infections with Anti-TNF Therapy: **Cohen, B.L.**

Anti-TNF Therapy in Crohn's Disease

- The 'Ideal' Anti-TNF Patient: Indications for Anti-TNF Therapy in Crohn's Disease: **Tran-Minh, M.-L. et al.**
- Predictor of Treatment Response: **Tanaka, H.; Motoya, S.**
- Step-Up or Top-Down, Combination with Immunosuppression or Not? **Barthel, C.; Stange, E.F.**

Anti-TNF Therapy in Ulcerative Colitis

- The 'Ideal' Anti-TNF Patient: Indications for Anti-TNF Therapy in Ulcerative Colitis: **Hisamatsu, T.**
- Predictors of the Treatment Response: **Kim, H.J.**
- What Is the Right Dosage? **Michetti, P.**

Anti-TNF Therapy in Special IBD Situations

- Fistulizing and Strictureing Crohn's Disease: **Schoepfer, A.M.**
- Postoperative Anti-TNF Therapy in the Management of Crohn's Disease: **Barrie, A.; Regueiro, M.**
- Anti-TNF- α Therapy for Extraintestinal Manifestations of IBD: **Nielsen, O.H. et al.**
- Anti-TNF Therapy in Special Situations of the Patient
- Anti-TNF Alpha Agents and Breastfeeding: **Al-Sum, H.; Maxwell, C.V.**
- Anti-TNF Therapy before Surgery: **Vavricka, S.R. et al.**

When and How to Stop Anti-TNF Treatment in IBD

- When and How to Stop Anti-TNF Treatment in Inflammatory Bowel Disease: Predictors of Relapse after Stopping Treatment: **Louis, E.**
- Treatment Options after Anti-TNF Failure: **Kobayashi, T.**

The easiest way to order: www.karger.com/fgare

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, f: +41 61 306 12 34
www.karger.com

KARGER 125 YEARS